期刊文献+

咪达唑仑、异丙酚与阿芬太尼联合催眠作用的模型化评价 被引量:5

Modeling based evaluation of the hypnotic and anaesthetic interactions between midazolam,propofol and alfentanil
原文传递
导出
摘要 目的 3个临床麻醉药咪达唑仑(X_1)、异丙酚(X_2)与阿芬太尼(X_3)单用和不同组合联用,可使手术病人获得不同的催眠作用。由于其间存在复杂的相互作用,已有的研究尚未完全阐明,有必要重新进行定量评价。方法本研究基于文献数据,采用权重配方模型进行定量分析和模拟研究,寻找临床优化组方。结果权重配方模型成功地建立,显示3个组分均存在明显的量效关系,其中X_3>X_2>X_1,彼此间有较强的协同作用;联合使用的量效曲线较陡,受试者对联合用药敏感,易于获得满意疗效。通过基于最终模型的模拟,列出了若干种临床用药方案供临床选择应用。结论权重配方模型可以有效地应用于麻醉药相互作用分析,可提供临床联合用药所需的各类信息。 Objective To reevaluate the hypnotic interactions between midazolam,propofol and alfentanil by the approach of modeling and simulation. Methods The weighted modification model was used to analyze the interactions among the three drugs based on the data from a published paper,and then the simulations of doses were conducted for combinations. Results The model was fitted to the data successfully,and indicated that the three drug presented an apparent dose- effect relationship with alfentanil 〉propofol〉 midazolam. The strong synergy existed among the three drugs. The subjects showed a significant response to the combinations. The simulations displayed the schemes of combinations for clinical practice. Conclusion The weighted modification model is a valid approach to identify optical combinations for guiding rational administration of the three drugs, and the model can fully interpret the characteristics of interactions.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2016年第7期646-648,共3页 The Chinese Journal of Clinical Pharmacology
基金 上海市中医药事业发展三年行动计划基金资助项目(ZY3-CCCX-3-1001) 上海市中药学一流学科创新研究基金资助项目(ZYX-CXYJ-003) 上海市支持基金资助项目(085ZY1202) 上海市教委预算内科研基金资助项目(2013JW19)
关键词 咪达唑仑 异丙酚 阿芬太尼 药物相互作用 协同 权重配方模型 midazolam propofol alfentanil drug intereaction synergy weighted modification model
  • 相关文献

参考文献2

二级参考文献55

  • 1盛玉成,郑青山.群体药代动力学及其在新药研究中的应用[J].中国临床药理学与治疗学,2004,9(12):1333-1337. 被引量:8
  • 2Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001; 88: 504–8. 被引量:1
  • 3Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J Cardiovasc Risk 2001; 8: 383–90. 被引量:1
  • 4Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, et al. Effects of rosuvastatin compared over 52 weeks for treatment in patients with hypercholesterolemia. Am Heart J 2002; 144: 1044–51. 被引量:1
  • 5Carswell CI, Plosker GL, Jarvis B. Rosuvastatin. Drugs 2002; 62: 2075–85. 被引量:1
  • 6Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92: 152–60. 被引量:1
  • 7Rader DJ, Davidson MH, Caplan RJ, Pears JS. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Am J Cardiol 2003; 91: 20C–23C. 被引量:1
  • 8McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001; 87: 28B–32B. 被引量:1
  • 9Leonard KA. Treatment and prevention of dyslipidemia with rosuvastatin (Crestor). Nurse Pract 2004; 29: 11–5. 被引量:1
  • 10Martin PD, Warwick MJ, Dane AL, Cantarini MV. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin Ther 2003; 25: 2215–24. 被引量:1

共引文献17

同被引文献43

引证文献5

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部